- Cytovance Biologics has introduced in-house formulation development services to expand its CDMO offering.
Cytovance Biologics, a U.S.-based Contract Development and Manufacturing Organization (CDMO), has launched in-house formulation development services. The move expands the company’s portfolio and positions it as a more integrated partner for biotech and pharmaceutical clients.
The new services, available immediately, are designed to accelerate development timelines and provide a streamlined approach for biologic drug developers.
Axel Schleyer, Chief Commercial Officer of Cytovance Biologics, said: “Adding formulation development capabilities is a major milestone for us. It allows us to better serve our clients by accelerating development timelines and providing a truly integrated one-stop-shop approach, all while maintaining the highest standards of quality and regulatory compliance.”
According to the company, the formulation development workflow is built on Quality by Design (QbD) principles, aiming to deliver speed, safety, and data-driven precision from the outset. The in-house expertise is expected to strengthen technical capabilities and enhance client support across complex drug development programmes.
